The aromatic fatty acid phenylbutyrate (PB) induces cytostasis, differentiation, and apoptosis in primary myeloid leukemic cells at clinically achievable concentrations. In the present study, we have investigated the structural and cellular basis for PBinduced cytostasis, using the ML-1 human myeloid leukemia cell line as a model system. PB induced a dose-dependent increase in cells in G1 with a corresponding decrease in cells in S-phase of the cell cycle. At comparable doses, PB induced expression of CD11b, indicating myeloid differentiation. At higher doses, the drug induced apoptosis. The antitumor activity was independent of the aromatic ring, as butyric acid (BA) was of equal or greater potency at producing these biological changes. In contrast, shortening of the fatty acid carbon chain length, as demonstrated with phenylacetate (PA), significantly diminished drug potency. Consistent with their effects on cell cycle, PB and BA, but not PA, induced the cyclindependent kinase inhibitor, p21
Introduction
The induction of terminal differentiation is usually associated with cell cycle arrest, and/or apoptosis. 1 Either outcome would potentially impair net expansion of a malignant clone, and yield a reduction in tumor burden. Manipulation of the capacity of leukemic cells to undergo differentiation may represent an alternative therapeutic strategy, which may be less toxic than cytotoxic chemotherapy. Pharmacologic induction of differentiation has already proved feasible in the case of acute promyelocytic leukemia. 2 Potential therapeutic benefits of differentiation therapy include enforced clonal differentiation leading to improved hematopoiesis in patients with myelodysplasia and cytopenias, and prolongation of remission duration in patients with acute myeloid leukemia and residual disease following conventional therapy.
We have recently shown that the aromatic fatty acid compound phenylbutyrate (PB) induces differentiation and inhibits the growth of primary leukemic cells 3 at concentrations similar to those achieved in patients receiving this drug for inborn errors of metabolism. 4 Its metabolite, phenylacetate (PA), which has been shown to induce differentiation in vitro in various leukemic and solid tumor cells, 5, 6 had little effect on the proliferation of these primary leukemic cells. 3 In the present work, we have evaluated the structural and cellular basis for PB-induced growth inhibition using the ML-1 human myeloid leukemia cell line as a model system. 7 Like most primary acute myeloid leukemias, 8 this cell line harbors wildtype p53. 7 We report that PB induces G1 arrest, differentiation and apoptosis in treated ML-1 cells. By comparing the activities of PB with those of PA and butyric acid (BA), we demonstrate that the fatty acid moiety of PB, but not its aromatic ring, is essential for the in vitro antitumor properties of the drug. Focusing on the molecular mechanism that may underlie drug-induced cytostasis, we demonstrate that PB and BA, but not PA, induce p21 WAF1/CIP1 expression and Rb hypophosphorylation, at the same concentrations required for growth inhibition. These data implicate p21 WAF1/CIP1 and Rb as cellular mediators of PB-induced growth arrest, and support the development of PB in clinical trials of patients with hematologic malignancies.
Materials and methods

Drugs
PB and PA were supplied by Elan Pharmaceuticals (Gainesville, GA, USA). Butyric acid (sodium salt) was purchased from Sigma (St Louis, MO, USA). All drugs were stored at room temperature. Fresh stock solutions (1 m) in distilled water were prepared the day of each experiment. Phorbol 12-myristate 13-acetate (TPA) was purchased from (Sigma); stock solution (1 m) was made in dimethyl sulfoxide (American Type Culture Collection, Rockville, MD, USA).
CD11b expression
Expression of the myelomonocytic marker CD11b was assayed as previously described, 9 using phycoerythrin-labeled CD11b antibody (clone 2LPM19C, Dako, Carpinteria, CA, USA). Cells labeled with equivalent concentration of phycoerythrin-labeled irrelevant mouse monoclonal IgG1 (DAK G-01, Dako), served as negative control. Fluorescence was measured on a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA). As previously described, mean channel number was converted to mean fluorescence intensity. 10 Mean fluorescence intensity of identically treated cells labeled with the irrelevant antibody was subtracted from each experimental value. 10 
Cell cycle analysis
Cell cycle was analyzed using flow cytometry of cells pulsed with bromodeoxyuridine (BrdU) through a modification of Dolbeare's technique, 11, 12 as follows. Aliquots of growing leukemic cells were pulsed with BrdU (10 m, 4 h, 37°C, Sigma). Cells were fixed in 70% MeOH (−20°C, 5 min), then denatured in 0.1 n HCl with 0.7% Triton X-100 (TX-100, Sigma) in PBS (0°, 10 min) before boiling in 0.003 n HCl (10 min). Cells were then incubated with anti-BrdU (30 min, 4°C, Becton Dickinson) in 0.5% Tween 20 (Sigma)/Hepes-buffered saline with 4% newborn bovine serum, washed twice, and incubated with FITC-conjugated goat anti-mouse IgG1 (Southern Biotechnologies, Birmingham, AL, USA, 40 min, 4°C). Cells were subsequently incubated with RNAse A (Sigma) in PBS (100 U/ml) at 37°C for 15 min, before the addition of an equal volume of propidium iodide in PBS, (50 g/ml, PI, Sigma) and incubation for 1 h at 4°C. Identically treated samples pulsed with medium instead of BrdU served as negative controls, and untreated ML-1 cells pulsed with BrdU were positive controls.
Immunoblot analysis
Cells were harvested, washed, and solubilized in Laemmli sample buffer as described previously. 13 Protein in each sample was quantified (Bio-Rad, Hercules, CA, USA), and 50 g of total cellular protein was separated by SDS-PAGE. Proteins were transferred on to nitrocellulose membranes, and equivalent transfer was confirmed by fast green staining of membranes. 13 Primary murine monoclonal antibodies to human p21 WAF1/CIP1 (Ab-1, PharMingen, San Diego, CA, USA) and Rb (1401A, PharMingen) were used in immunoblots, which were then stained with horseradish peroxidase-conjugated secondary antibodies. Autoradiography was carried out using enhanced chemiluminescence (Amersham Life Sciences, Thousand Oaks, CA, USA). Band density was quantified on a FastScan densitometer (Molecular Dynamics, Sunnyvale, CA, USA), with volume integration using ImageQuant software (Molecular Dynamics).
Flow cytometric assay for p21 WAF1/CIP1 detection
In order to quantify relative expression of p21 WAF1/CIP1 in individual cells, a flow cytometric assay for p21 WAF1/CIP1 was established. A technique used to identify other intracellular antigens such as c-myc, 10 terminal deoxynucleotidyl transferase, 14 and Ki67 15 was adapted. 1 × 10 5 -1 × 10 6 cells were washed twice in Hepes-buffered saline with 4% newborn bovine serum (IFA medium) before fixation in 2 ml ice-cold 1% formaldehyde (ultra-pure, EM grade, Polysciences, Warrington, PA, USA) in phosphate-buffered saline for 10 min as previously described. 10, 14, 15 Cells were then permeabilized with 2 ml ice-cold 0.1% TX-100 in IFA medium for 3 min, pelleted, then incubated with unlabeled anti-p21 WAF1/CIP1 antibody (Ab-1) in 100 l of IFA medium for 30 min on ice. The cells were washed twice in 0.1% TX-100/IFA before incubation with fluorescein (FITC)-labeled secondary antibody for 30 min (Southern Biotechnologies). Cells were again washed twice in 0.1% TX-100/IFA and resuspended in IFA medium. Cells labeled with an equivalent concentration of irrelevant mouse monoclonal IgG1 (Dak G-01) served as a negative control. Fluorescence was analyzed on the day of experiment using a FACScan flow cytometer (Becton Dickinson).
Apoptosis
Apotosis was assessed through binding of Annexin V. 16 Cells were washed in PBS and incubated in 0.9% NaCl containing 5 mm EDTA for 15 min. Cells were then washed in ice-cold PBS before resuspension in ice-cold binding buffer (R&D Systems, Minneapolis, MN, USA). Negative control cells were resuspended in 5 mm EDTA. 10 l each of FITC-conjugated Annexin V (10 g/ml, R&D) and propidium iodide (50 g/ml in PBS) were added, and cells were incubated on ice for 10 min in the dark. Fluorescence was measured immediately on the flow cytometer. Annexin V+PI− cells (early apoptosis) were quantified separately from Annexin V+PI+ cells (late apoptosis plus necrosis); however, the results of dose-and time-response curves were identical using these two analyses (data not shown). In this manuscript we report the total Annexin V+ values.
Statistical considerations
ED 50 was calculated as previously described. 17 Correlations were tested using linear regression analysis. Means were compared using two-tailed Student's t-test.
Results
PB and BA induce differentiation of ML-1 cells
Exposure to PB and BA, but not PA induced a time-and dosedependent increase in expression of the myelomonocytic cell surface protein CD11b in ML-1 cells (Figure 1 ). CD11b expression was increased over control after as little as 1 day of incubation, but was dramatically increased by day 7. Comparing the potency of these three compounds, BA was more potent than PB; ED50 for BA was 0.5 ± 0.03 mm while ED50 for PB was 2.1 ± 0.4 mm (P Ͻ 0.02). Maximal induction of CD11B expression by BA was also greater than by PB (sevenvs five-fold on day 7). PA effected no significant increase in CD11b expression.
Wright-Giemsa stained PB-treated ML-1 cells (treated at doses of PB which induce CD11b expression) appeared somewhat larger and more granular than untreated cells. No cells underwent complete differentiation to mature granulocytes or monocytes (data not shown). At doses of PB of 2.5 mm and higher, evidence of apoptosis (nuclear karryorhexis and apoptotic bodies) was clearly seen in many cells (data not shown, see below for further documentation of apoptosis).
PB and BA induce G1 cell cycle arrest
Although PB is known to induce cytostasis in tumor cell lines, its impact on cell cycle distribution has not been reported. Treatment with PB and BA led to a progressive decline in the fraction of S-phase cells ( Figure 2 ). As with CD11b expression, BA was more potent than PB, with respective ID 50 s 1.4 ± 0.01 vs 2.2 ± 0.07 mm (P Ͻ 0.001). Inhibition of S-phase cells was seen as early as day 1 of incubation with both of these drugs. PB and BA induced comparable maximal inhibition of S- phase. Accompanying the decline in the proportion of PB-and BA-treated cells in S-phase, there was an increase in cells in G1 phase, implying a drug-induced G1 arrest (Figure 2 ). Of interest, low doses of PB (р1 mm) consistently led to a slight increase in S-phase cells on days 2-3 of incubation. As with CD11b induction, induction of G1 arrest did not appear to depend on the aromatic ring, as treatment with PA led to very modest modulation of cell cycle parameters.
Drug-induced p21 WAF1/CIP1 synthesis correlates with cell cycle arrest and Rb hypophosphorylation
The cyclin-dependent kinase inhibitor, p21 WAF1/CIP1 plays a significant role in the G1 arrest induced by ␥-irradiation, 18, 19 at least in part by inhibiting phosphorylation of Rb (reviewed in Ref. 20) . Several groups have also demonstrated induction of p21 WAF1/CIP1 by differentiating agents in myeloid leukemia induction and the resultant hypophosphorylation of Rb are responsible for the growth arrest that precedes terminal myeloid differentiation. We evaluated the levels of p21 WAF1/CIP1 protein in ML-1 cells treated with PB, BA or PA for 3 days. Both PB and BA induced p21 WAF1/CIP1 at concentrations which induce G1 arrest (0-2.5 mm, Figure 3a ). In contrast, PA exposure did not significantly increase p21 WAF1/CIP1 expression relative to the control (Figure 3a) , correlating with its inability to induce G1 arrest. The proportion of Rb in the hypophosphorylated state increased in conjunction with p21 WAF1/CIP1 , in PB-treated cells (Figure 3b ). BA-treated, but not PA-treated cells, showed similar changes in phosphorylated Rb (data not shown).
To facilitate future exploration of p21 WAF1/CIP1 expression in individual cells, a flow cytometric assay for this protein was established (see Materials and methods). Using this assay, untreated ML-1 cells had no detectable fluorescence signal (Figure 4a ). In contrast, exposure to relevant doses of PB or TPA for 3 days led to detectable p21 WAF1/CIP1 signal. The intensity of the fluorescence signal increased with increasing doses of PB (Figure 4b ). To validate this assay, ML-1 cells were treated with a variety of doses of PB or TPA, and individual samples were analyzed by both immunoblot and flow cytometric assay. The band density on immunoblot was compared to the percentage of cells containing positive fluorescence signal by flow cytometry for each sample, and regression analysis was performed (Figure 4c ). Fluorescence signal correlated well with p21 WAF1/CIP1 expression as measured by immunoblot (r 2 = 0.77; P Ͻ 0.001). The flow cytometric assay was used to explore the time course and dose response characteristics of induction of p21 WAF1/CIP1 by PB and its cogeners ( Figure 5 ). In response to PB and BA, p21 WAF1/CIP1 expression peaked on day 3; again PB was slightly less potent than BA (ED50 2.0 ± 0.08 mm vs 1.5 ± 0.05 mm, respectively, P Ͻ 0.01), with maximal induction 30 ± 6% vs 50 ± 11% cells positive, respectively (P, not significant). Although p21 WAF1/CIP1 expression was greatest on day 3, increased expression could still be detected on day 7 of incubation. This time course and dose-response mimicked that of BA-and PB-induced cell cycle arrest (see above). Results were similar if mean fluorescence intensity was used to analyze the cytograms rather than 'percent positive cells' (data not shown). Exposure of ML-1 cells to doses of PA as high as 5 mm for 7 days resulted in no detectable expression of p21 WAF1/CIP1 using the flow cytometric assay.
Drug-induced apoptosis
Myeloid differentiation in tumor cells may be accompanied by apoptosis in addition to cell cycle arrest, 3 as is also seen in normal myelopoiesis. 24 To assess whether PB-induced cell cycle arrest is accompanied by induction of apoptosis, apoptosis was assayed using Annexin V (Figure 6 ). Both PB and BA induced apoptosis at doses greater than 1 mm. The difference in potency between PB and BA for the induction of apoptosis was less than for other parameters (ED 50 3.6 ± 0.12 and 3.09 ± 0.09, respectively, P Ͻ 0.02). The ED 50 for induction of apoptosis was approximately twice that for cell cycle arrest, p21 WAF1/CIP1 induction, and induction of CD11b expression. No apoptosis induction was seen at doses of PA as high as 10 mm. Data obtained with Annexin V was comparable to data obtained using a TUNEL technique (Refs 25 and 26, data not shown).
Discussion
Although cytotoxic chemotherapy induces remission in many patients with acute myeloid leukemia and myelodysplasia, elderly patients frequently cannot tolerate the side-effects of conventional therapy. For these patients, differentiation therapy might provide an alternative, potentially less toxic mode of treatment. In patients with MDS or AML, differentiation therapy may be of therapeutic benefit in several ways: (1) by enforcing differentiation of clonal disease and improving cytopenias; (2) by inducing terminal differentiation, and thereby, clonal extinction; and (3) by suppressing the growth of residual disease, and thereby extending remission duration, in patients who have undergone prior induction therapy. Unfortunately, previous clinical trials of other differentiating agents in patients with AML and MDS, including 1,25 dihydroxyvitamin D 3 and hexamethylene bisacetamide (HMBA), have been hampered by the inability to achieve adequate plasma levels of drug, and poor therapeutic indices. [27] [28] [29] Recently, the aromatic fatty acids, PB and PA, have been shown to induce differentiation in hematopoietic 5, 6 and solid tumor 30, 31 cell lines. Although millimolar concentrations of these compounds are required to induce differentiation in vitro, prior clinical studies in children and adults indicate that pharmacologic doses of these compounds are attainable without serious side-effects. 4, 32 Using primary leukemic cells treated in vitro, we have shown that PB, but not PA, inhibits proliferation associated with induction of expression of lineage-and differentiation stage-specific cell surface proteins at these concentrations. 3 As an extension of these findings, we used the human myeloid leukemia cell line, ML-1, as a model system to evaluate further the structural requirements and molecular basis of PB-induced cytostasis in hematologic malignancies.
Unlike many hematopoietic cell lines, primary AML leukemic blasts do not typically harbor p53 abnormalities. 8 Prior work with PA in hematopoietic cell lines has been limited to those harboring abnormalities in p53. 5, 6 This latter point is critical in light of the demonstrated role of wild-type p53 in myeloid differentiation, 33, 34 cell cycle arrest, 7, 35 and apoptosis. 36 Therefore, the ML-1 cell line, which is p53 wildtype, 7 may more faithfully reflect primary human disease than p53 null cell lines with respect to growth inhibition by PB. Along these lines, we note that CFU-L from patients with AML and MDS have ID 50 values for PB between 0.3 mm and 1.8 mm, 3 similar to those found here using ML-1 cells. Prolongation of or arrest in G 1 may be a characteristic and important event in induction of differentiation. Arrest of cells in G 1 in response to differentiating agents has been noted in phorbol ester-induction differentiation of HL-60, 37 ,38 U-937, and THP-1 cells. 38 Induction of cellular differentiation by vitamin D 3 and analogues, as well as the tyrosine kinase inhibitor herbicmycin A are also associated with G 1 arrest. 39, 40 Exposure to the polar planar differentiation inducer HMBA causes a number of potentially important metabolic events which lead to cell cycle arrest. These include down-regulation of p107, cdk4, and accumulation of underphosphorylated RB and p130, [41] [42] [43] associated with prolongation of G 1 . 44 Blockage of formation of the pRB:E2F and p 130:E2F complexes through enforced expression of human papillomavirus 16 E7 led to induction of apoptosis by HMBA rather than induction of differentiation. 43 Okadaic acid-inhibition of protein phosphatases involved with dephosphorylation of RB also inhibits HMBA-induced terminal differentiation. 45 HMBA analogues which induce differentiation at micromolar concentration also induce accumulation of underphosphorylated RB, increased levels of p21 WAF1/CIP1 , and prolongation of G 1 .
46
The aromatic fatty acid, PB, and the aliphatic fatty acid, butyrate, both of which share a four-carbon fatty chain, produced G 1 cell cycle arrest of ML-1 cells and apoptosis at relevant concentrations, whereas PA, an aromatic fatty acid with a 2-carbon chain, did not. Similarly, PB and butyrate, but not PA, induced p21 WAF1/CIP1 , and led to hypophosphorylation of Rb. This correlation is consistent with a mechanistic role for p21 WAF1/CIP1 in the cell cycle arrest that accompanies differentiation induced by PB and butyrate. The loss of growth inhibitory activity resulting p21 WAF1/CIP1 from shortening of the fatty acid chain length from four carbons to two carbons implicates the fatty acid moiety in PB as a critical effector of growth inhibition and p21 WAF1/CIP1 induction. In contrast, the aromatic ring of PB was dispensable with respect to both activities. It is of interest that low doses of PB appear to cause a transient increase in percentage of cells in S-phase. This suggests that different dose ranges of PB may impact differently on cell cycle regulatory genes, with potential augmentation of proliferation at very low doses, and growth inhibition (G 1 arrest detailed in this paper) at higher doses.
Although BA appears somewhat more potent than PB in vitro, PB offers certain advantages for clinical use, including a significantly longer half-life in humans (1 h vs 6 min) 47, 48 and the ability to reduce the levels of circulating glutamine, an amino acid essential for the survival of malignant cells. 49 In human breast carcinoma cells, p21 WAF1/CIP1 -wild-type, but not p21 WAF1/CIP1 -null cells, undergo growth arrest after treatment with PA, providing strong evidence for the role of p21 WAF1/CIP1 in PA-mediated cytostasis. 50 p21 WAF1/CIP1 is known to be induced by differentiating agents in a number of myeloid leukemia cell lines. 1, [21] [22] [23] 51 Taken together, these findings indicate that the aromatic fatty acids may induce cell cycle arrest via p21 WAF1/CIP1 in susceptible malignant cells, and identify PB as the preferred drug for the treatment of myeloid malignancies.
The molecular mechanism by which these drugs exert pharmacodynamic effect is not clear. PB has been shown to impact on expression of peroxisome proliferation associated receptors, 52 protein isoprenylation, 31 DNA methylation 30 and histone acetylation. 53 Butyric acid is undergoing intensive study as an inhibitor of histone deacetylase. Trichostatin A, a prototype histone deacetylase inhibitor, can induce expression of p21 WAF1/CIP1 in some systems. 54 The specific pharmacodynamic effects induced by these drugs may result from their impact on one specific molecular pathway, or several. The significant differences between ED 50 for induction of apoptosis and for cell cycle arrest/CD11b induction by both PB and BA suggests that these drugs may mediate these cellular changes through different molecular mechanisms.
Figure 6
Induction of apoptosis by PB and BA, but not PA. ML-1 cells were incubated with various doses of drugs for the indicated times before measurement of apoptosis using Annexin V binding. Data represent the mean ± s.e.m. of three separate experiments.
Both PB and BA require millimolar concentrations to elicit pharmacodynamic effects. Such concentrations have been safely achieved in the clinical treatment of patients with hemoglobinopathies and metabolic disorders with PB; 48, 49, 55, 56 however, they may be difficult to maintain chronically. Chronic treatment with PB may provide a strategy to elicit a therapeutic effect without the need to maintain unrealistically high serum concentrations of drugs. Combination of PB with other therapies may further reduce the concentrations of drugs required for cytostasis and/or cytotoxicity. 57 Better understanding of the specific cellular pathways which lead to the pharmacodynamic effects of these drugs may lead to the development of more specific and potent cogeners which will prove more practical for clinical use.
